CHIGLITAZAR FOR THE TREATMENT OF MASH PHASE II CLINICAL STUDY SELECTED FOR ORAL PRESENTATION AT THE 2024 AMERICAN LIVER DISEASE ANNUAL MEETING

Reuters · 10/15 14:09

Please log in to view news